VivoSeq
Other

HSCT

0

Pipeline Programs↗

3

Active Trials↗

2

Companies Involved↗

HSCT is an early-stage landscape with 0 programs across 2 companies. The most active players are Xiamen Amoytop Biotech Co., Ltd., Bellicum Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

X

Xiamen Amoytop Biotech Co., Ltd.

0 programs

PreclinicalB

Bellicum Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

20

clinical trials

Completed8 · 40%
Unknown status5 · 25%
Terminated3 · 15%
Recruiting2 · 10%
Not yet recruiting1 · 5%
Withdrawn1 · 5%

Clinical Trials

Trial Activity

20 trials

Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.
Recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 2·NCT06483906·56 enrolled
Defibrotide Dose-escalation for SOS Post-HSCT
Recruiting·NNew York Medical College·Phase 2·NCT05987124·20 enrolled
AZA Combined With NAC for PIT After HSCT
Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT05126004·100 enrolled
Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT
Completed·SShenzhen Second People's Hospital·Phase 3·NCT03515096·98 enrolled
A Study of FMT in Patients With AML Allo HSCT in Recipients
Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT03678493·100 enrolled
Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT
Completed·XXiamen Amoytop Biotech Co., Ltd.·Phase 4·NCT01232504·206 enrolled
The Use of Eltrombopag Post HSCT in BMFD
Completed·TThe First Affiliated Hospital of Soochow University·Phase 2/3·NCT05466201·118 enrolled
Protein A Immunoadsorption in Highly Sensitized Haplo-HSCT Patients
Completed·TTing YANG·N/A·NCT07200583·50 enrolled
Safety Study of ADV-specific T-cells in Paediatric Patients Post Allo-HSCT
Completed·CCell Medica Ltd·Phase 1/2·NCT01822093·8 enrolled
Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs
Completed·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT01033552·32 enrolled
Prospective Assessment of Functional Status, Psychosocial Adjustment, Health Related Quality of Life and the Symptom Experience in Patients Treated With Allogeneic Hematopoietic Stem Cell Transplantation
Completed·National Institutes of Health Clinical Center (CC)·N/A·NCT00128960·173 enrolled
ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT
Terminated·—·Phase 2·NCT04785547·3 enrolled
Panobinostat Maintenance After HSCT fo High-risk AML and MDS
Terminated·GGoethe University·Phase 3·NCT04326764·52 enrolled
Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS
Terminated·BBellicum Pharmaceuticals·Phase 2/3·NCT03699475·1 enrolled
QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML
Withdrawn·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT03365661
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)